Microbot Medical (MBOT) Q4 2024 earnings summary

Executive summary

• Clinical-stage medical device company focused on robotic endoluminal surgery, primarily developing the LIBERTY® Endovascular Robotic Surgical System targeting minimally invasive vascular interventions.

• No revenue generated to date; operations funded through equity, grants, and convertible debt, with cumulative losses of $90.9 million since inception.

• Significant milestones in 2024 include completion of pivotal preclinical and human trials, 510(k) submission to FDA, and ISO 13485:2016 certification.

• Raised over $30 million in early 2025, extending liquidity for more than one year from the financial statement issuance date.

Financial highlights

• Net loss for 2024 was $11.4 million, compared to $10.7 million in 2023.

• Research and development expenses increased to $6.6 million in 2024 from $5.7 million in 2023, driven by higher headcount, regulatory, and clinical costs.

• General and administrative expenses rose to $5.0 million in 2024 from $4.1 million in 2023.

• Cash, cash equivalents, and marketable securities totaled $5.5 million as of December 31, 2024, not including subsequent capital raises.

• Working capital was $3.4 million at year-end 2024, down from $4.1 million at year-end 2023.

Outlook and guidance

• Anticipates FDA marketing clearance for LIBERTY® in Q2 2025, with U.S. commercialization to follow.

• Expects CE Mark approval in Europe in the second half of 2026.

• Plans to continue investing in R&D and expand commercialization and sales teams upon regulatory clearance.